Adsorption of a novel recombinant glycoprotein from HIV (env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not

Pharmaceutical Research

Volumn 21, Issue 12, 2004, Pages 2148-2152

  Singh, Manmohan ^a   Chesko, James ^a   Kazzaz, Jina ^a   Ugozzoli, Mildred ^a   Kan, Elaine ^a   Srivastava, Indresh ^a   O'Hagan, Derek T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CD4; gp120; HIV; Microparticle; Vaccine

Indexed keywords

CD4 ANTIGEN; DOCUSATE SODIUM; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; POLYGLACTIN; RECOMBINANT GLYCOPROTEIN GP 120; RG 503; VACCINE;

ADSORPTION; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMULSION; ENCAPSULATION; EVAPORATION; FEASIBILITY STUDY; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REDUCTION; SURFACE PROPERTY;

ADSORPTION; ANIMALS; ANTIGENS, CD4; CHO CELLS; CRICETINAE; DRUG COMPOUNDING; HIV ENVELOPE PROTEIN GP120; HIV-1; MICROSPHERES; PROTEIN BINDING; RECOMBINANT PROTEINS;

EID: 17644426388     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-7666-6     Document Type: Article

References (21)

1. E. A. Emini and W. C. Koff. Developing an AIDS vaccine: need, uncertainty, hope. Science 304:1913-1914 (2004).
2. D. A. Garber, G. Silvestri, and M. B. Feinberg. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4:397-413 (2004).
3. S. C. Sookoian. New therapies on the horizon for hepatitis C. Ann Hepatol. 2:164-170 (2003).
4. S. E. Frey. HIV vaccines. Infectious Disease Clin. North America 13:95-112 (1999).
5. J. Esparza. An HIV vaccine: how and when? Bull. World Health Organ. 79:1093 (2001).
6. J. L. Cleland, M. F. Powell, A. Lim, L. Barron, P. W. Berman, D. J. Eastman, J. H. Nunberg, T. Wrin, and J. C. Vennari. Decelopment of a Single-Shot Subunit Vaccine for HIV-1. AIDS Res. Hum. Retroviruses 10(Suppl 2):21-26 (1994).
7. J. L. Cleland. Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems. Pharm. Biotechnol. 6:439-462 (1995).
8. D. O'Hagan, M. Singh, M. Ugozzoli, C. Wild, S. Barnett, M. Chen, M. Schaefer. B. Doe, G. Otten, and J Ulmer. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J. Virol. 75:9037-9043 (2001).
9. J. Kazzaz, J. Neidleman. M. Singh, G. Ott. and D. T. O'Hagan. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Controlled Release 67:347-356 (2000).
10. D. T. O'Hagan, M. Singh, J. Kazzaz, M. Briones, and J. Donnelly. and Ott, G. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20:3389-3398 (2002).
11. VaxGen. VaxGen announces initial results of its Phase III AIDS vaccine trial. Press release Feb 24, 2003. Available at http://www.vaxgen.com/pressroom/ index.html.
12. R. E. Johnson, L. A. Lanaski, V. Gupta. M. J. Griffin, H. T. Gaud, T. E. Needham, and H. Zia. Stability of atriopeptin III in poly (lactide-co-glycolide) microparticles. J. Controll. Rel. 17:61 (1991).
13. B. Bittner, M. Morlock, H. Koll, G. Winter, and T. Kissel. Recombinant human erythropoietin (rhEPO) loaded poly(lactideco-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteriztics. Eur. J. Pharm. Biopharm. 45:295-305 (1998).
14. R. Wyatt. P. D. Kwong, E. Desjardins. R. W. Sweet. J. Robinson, W. A. Hendrickson, and J. G. Sodroski. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711 (1998).
15. P. D. Kwong, R. Wyatt. J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659 (1998).
16. M. Singh and J. Kazzaz. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J. Pharm. Sci. Vol. 93(2):273-282 (2004).
17. D. T. O'Hagan. The prospects for the development of new and improved vaccines through the use of microencapsulation technology. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (Eds.), New Generation Vaccines. Second Ed., Marcel Dekker, New York. pp. 215-228 (1997).
18. A. Martin. Physical Pharmacy, 4th ed., Lea and Febiger, Philadelphia, 1993.
19. S. J. Seeber, J. L. White, and S. L. Hem. Predicting the adsorption of proteins and aluminum-containing adjuvants. Vaccine 9:201-203 (1991).
20. P. M. Callahan, A. L. Shorter, and S. L. Hem. The importance of surface charge in the optimization of antigen-adjuvant interactions. Pharm. Res. 8:851-857 (1991).
21. M. F. Chang and S. L. Hem. Role of the electrostatic attractive force in the the adsorption of proteins by aluminum hydroxide adjuvant. PDA J. Pharm. Sci. Technol. 51:1-5 (1997).